Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic lateral sclerosis (ALS) and similar disorders. The U.S. patent grants Avicenna exclusive rights to pharmaceutical products containing inhibitors of the Rho associated protein kinases 1 and 2 (ROCK1/2). It also…
Search results for:
NurOwn (debamestrocel) is an investigational cell-based therapy designed to slow disease progression and potentially extend survival in people with ALS. It is being developed by BrainStorm Cell Therapeutics to be given as regular intrathecal injections, or into the spinal canal.
Long-term treatment with the cell therapy NurOwn (debamestrocel) was found to significantly extend survival in people with amyotrophic lateral sclerosis (ALS) when compared with a matched control group from previous clinical trials, according to new data. That data, from an expanded access program (EAP), was shared by NurOwn’s…
Neurosense Therapeutics will meet with the U.S. Food and Drug Administration (FDA) Nov. 6 to discuss plans for a Phase 3 trial to test its experimental therapy PrimeC in amyotrophic lateral sclerosis (ALS). The company said it will give an update on results of the Type C meeting following…
A database integrating long-term respiratory data with natural history data from people with amyotrophic lateral sclerosis (ALS) has been made available to scientists globally, with the hopes of accelerating research and the discovery of new therapies. Developed under a collaboration between the nonprofit Target ALS and Zephyrx, the…
Woolsey Pharmaceuticals has received three new U.S. patents covering innovations related to Bravyl (oral fasudil), its investigational amyotrophic lateral sclerosis (ALS) medication. The patents cover the use of oral fasudil to slow the progression of sporadic ALS, as well as solid and liquid formulations of fasudil for people…
Treatment with Radicava ORS (edaravone) significantly slowed declines in physical function and improved survival outcomes for people with amyotrophic lateral sclerosis (ALS) compared with historical controls from the PRO-ACT database who’d received a placebo in previous clinical trials. The findings were presented by Mitsubishi Tanabe Pharma…
Neither memantine nor trazodone, two medications approved to treat other conditions, was able to slow disease progression in people with amyotrophic lateral sclerosis (ALS) who took part in a platform clinical trial, a study concluded. Based on the lack of benefits in the trial’s interim analysis, the two treatment…
An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS) in the European Union. The decision was taken in a meeting by the Committee for Medicinal…
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development by uniQure for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, when the condition is thus known as SOD1-ALS. The open-label EPISOD1 clinical…